MedTrace Logo

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Healthy Male Subjects

NCT05087069 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-01-17

No results posted yet for this study

Summary

Safety and tolerability and Pharmacokinetics of multiple doses of BV100 in healthy volunteers

Conditions

  • Healthy Volunteers

Interventions

DRUG

BV100

Rifabutin for Infusion

DRUG

Placebo

Saline intravenous infusion

Sponsors & Collaborators

  • Nuvisan GmbH

    collaborator UNKNOWN

  • BioVersys SAS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-08
Primary Completion
2022-04-08
Completion
2023-01-12

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05087069 on ClinicalTrials.gov